Management of Severe Side Effects after Chemotherapy in B-Cell Lymphoma

Immediate Intervention for Severe Side Effects

The European Society for Medical Oncology recommends immediate assessment of blood counts, liver and kidney function, and LDH to evaluate myelosuppression and organ complications in patients with severe side effects after chemotherapy for B-cell lymphoma 1, 2
In cases of febrile neutropenia (temperature ≥38°C with neutropenia), immediate hospitalization and empirical broad-spectrum antibiotic therapy are necessary 3

The European Society for Medical Oncology suggests using granulocyte-colony stimulating factors (G-CSF) to prevent further episodes of neutropenia, especially if febrile 3
Adequate hydration (intravenously in cases of severe dehydration) is crucial for patient management 1

Dose reduction of chemotherapy due to hematologic toxicity should be avoided, as it may decrease treatment efficacy 2, 3
Instead, prophylactic use of growth factors (G-CSF) should be considered to maintain full doses 2, 3
In cases of recurrent febrile neutropenia, prophylactic use of hematopoietic growth factors is justified 2, 3

The European Society for Medical Oncology recommends follow-up examinations every 3 months in the first year, every 6 months in the next 2 years, and annually thereafter 1, 2
Blood counts and LDH should be monitored at 3, 6, 12, and 24 months 1, 2
CT scans should be performed at 6, 12, and 24 months after completion of treatment 1, 2
Attention should be paid to the development of secondary tumors and other long-term side effects 1, 2
More than 30% of patients with DLBCL will experience relapse, making regular follow-up crucial 1